Genomma Lab Internacional, SAB de CV (BMV: LABB), a Mexico-based over-the-counter pharmaceutical, generic drugs and personal care products company, announced on Thursday a cash dividend of MXN0.200000 per share on its common stock.
This represents a total amount of MXN200m.
The dividend is payable to shareholders of record of the applicable circulating shares at the close of business on 14 March 2025.
Genomma Lab intends to make dividend payments on a quarterly basis.
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Labcorp declares quarterly dividend of USD0.72 per share
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases